TM Owner Generic
Milrinone 1mg/mL Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Milrinone (milrinone lactate) 1 mg/mL injection is a phosphodiesterase-3 inhibitor with inotropic and vasodilator activity, used for the short-term intravenous treatment of adults with acute decompensated heart failure, including patients who have not responded adequately to diuretics, vasodilators and conventional inotropic agents.
- It is given only in a hospital or intensive-care setting, with continuous cardiac and haemodynamic monitoring, and is not intended for chronic outpatient use or for heart failure caused by hypertrophic obstructive cardiomyopathy.
- Milrinone is supplied as a generic injectable, with several manufacturers, including Hikma Pharmaceuticals, producing equivalent milrinone lactate solutions for hospital use; the exact source depends on hospital procurement rather than a single branded product.
- It is used as a bridge while the underlying cause of decompensation is treated, or while awaiting more definitive interventions such as surgery, mechanical support or transplantation.
Side Effects
- Milrinone has no boxed warning, but it carries an important safety statement: long-term oral or intravenous use beyond 48 hours has not been shown to be safe, and has been linked to a higher risk of hospitalisation and death, so treatment duration is limited and closely supervised.
- The most common adverse effects seen with intravenous milrinone are heart rhythm disturbances: ventricular ectopic activity in around 1 in 12 patients, ventricular arrhythmias in roughly 1 in 8, and supraventricular arrhythmias in about 1 in 25.
- Low blood pressure and headache each occur in roughly 1 in 30 patients.
- Because milrinone can worsen abnormal heart rhythms and lower blood pressure, patients are monitored continuously on cardiac telemetry with blood pressure checks throughout the infusion.
- Tell hospital staff immediately about chest pain, palpitations, dizziness or fainting during treatment.
Precautions & Warnings
- Milrinone must not be used in patients with a known hypersensitivity to milrinone lactate.
- It requires continuous electrocardiographic monitoring during infusion because of its potential to cause or worsen ventricular and supraventricular arrhythmias, and blood pressure and fluid balance should be monitored closely, with dose reduction in significant renal impairment since milrinone is cleared largely by the kidneys.
- It is given by intravenous infusion only, usually after an initial loading dose followed by a continuous maintenance infusion titrated to clinical response; it must not be given as an unplanned bolus outside the recommended loading-dose protocol.
- Use with caution in patients with atrial fibrillation or flutter, as milrinone may increase the ventricular response rate.
- Correct low blood potassium before and during treatment, since it increases the risk of arrhythmia.
- Safety in pregnancy and breastfeeding has not been established.
Avoid Interactions
- Milrinone has not shown clinically important interactions in studies with digoxin, lidocaine, quinidine, hydralazine, prazosin, nitrates, diuretics, ACE inhibitors such as captopril, heparin, warfarin, diazepam, insulin or potassium supplements, so it is commonly used alongside these standard heart-failure medicines under hospital supervision.
- However, furosemide must never be injected into the same intravenous line as milrinone, because a chemical precipitate forms immediately when the two drugs mix; they must be given through separate lines or the line flushed thoroughly between doses.
- Because milrinone lowers blood pressure and can raise heart rate, use caution when combining it with other vasodilators or inotropes, as effects may add together.
- Tell the treating team about all other medicines and infusions being given, so line compatibility and combined cardiovascular effects can be checked before and during the infusion.
References
Frequently Asked Questions
Milrinone (milrinone lactate) is an intravenous heart medicine used for short-term treatment of acute decompensated heart failure in hospital. It strengthens the heart's pumping and widens blood vessels when other treatments like diuretics have not worked well enough.
Milrinone is given only in hospital, as an intravenous infusion, usually starting with a loading dose followed by a continuous drip adjusted to your response. Treatment is normally limited to a short course, with continuous heart monitoring throughout.
The main risks are abnormal heart rhythms, including ventricular arrhythmias in about 1 in 8 patients, and low blood pressure or headache in roughly 1 in 30. Because of this, your heart rhythm and blood pressure are watched continuously during the infusion.
Furosemide must never be injected into the same IV line as milrinone, since the two drugs form a precipitate together; separate lines are used. Low blood potassium should be corrected first, as it raises the risk of irregular heartbeat during treatment.
You will have continuous ECG heart-rhythm monitoring, regular blood pressure checks, and monitoring of kidney function and blood potassium throughout the infusion. Your dose may be adjusted or the infusion stopped if arrhythmias, low blood pressure, or kidney impairment develop.
No. Milrinone is intended for short-term use only; treatment beyond 48 hours has not been proven safe and has been linked to higher rates of hospitalisation and death. Your care team will use it for the shortest time needed.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
